Clinical Trial Detail

NCT ID NCT01592370
Title Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Bristol-Myers Squibb
Indications

chronic myeloid leukemia

Hodgkin's lymphoma

non-Hodgkin lymphoma

multiple myeloma

Therapies

Nivolumab

Ipilimumab

Lirilumab

Age Groups: adult

No variant requirements are available.